Tags

Type your tag names separated by a space and hit enter

Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline.
Clin Infect Dis. 1999 Dec; 29(6):1502-6.CI

Abstract

Malaria prophylaxis for travelers is a controversial issue. The commonly used regimens are associated with side effects, low compliance, or low efficacy, which have raised concern regarding their use. In addition, they are inefficient against the tissue stage of the parasite and thus do not prevent relapses of Plasmodium vivax infection. Primaquine is aimed at the pre-erythrocytic stage and thus may be a potential causal-prophylactic treatment that can abolish the need for long postexposure therapy. During 1995-1998, we followed retrospectively travelers who joined rafting trips to an area in Ethiopia where both P. vivax and Plasmodium falciparum are hyperendemic. Of the 106 travelers who received primaquine, 5.7% developed malaria; of the 19 doxycycline recipients, 53% developed malaria; and of the 25 mefloquine recipients, 52% developed P. vivax malaria (>/=3 months after return from the area of endemicity). Primaquine was well tolerated, and only 1 withdrawal from therapy (due to gastrointestinal symptoms) was reported. Primaquine was shown to be a safe and effective prophylactic drug against both P. falciparum malaria and P. vivax malaria in travelers.

Authors+Show Affiliations

Center for Geographical Medicine and Department of Medicine C, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel. elischwa@post.tau. ac.il.No affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

10585803

Citation

Schwartz, E, and G Regev-Yochay. "Primaquine as Prophylaxis for Malaria for Nonimmune Travelers: a Comparison With Mefloquine and Doxycycline." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 29, no. 6, 1999, pp. 1502-6.
Schwartz E, Regev-Yochay G. Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline. Clin Infect Dis. 1999;29(6):1502-6.
Schwartz, E., & Regev-Yochay, G. (1999). Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 29(6), 1502-6.
Schwartz E, Regev-Yochay G. Primaquine as Prophylaxis for Malaria for Nonimmune Travelers: a Comparison With Mefloquine and Doxycycline. Clin Infect Dis. 1999;29(6):1502-6. PubMed PMID: 10585803.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline. AU - Schwartz,E, AU - Regev-Yochay,G, PY - 1999/12/10/pubmed PY - 2000/3/21/medline PY - 1999/12/10/entrez SP - 1502 EP - 6 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 29 IS - 6 N2 - Malaria prophylaxis for travelers is a controversial issue. The commonly used regimens are associated with side effects, low compliance, or low efficacy, which have raised concern regarding their use. In addition, they are inefficient against the tissue stage of the parasite and thus do not prevent relapses of Plasmodium vivax infection. Primaquine is aimed at the pre-erythrocytic stage and thus may be a potential causal-prophylactic treatment that can abolish the need for long postexposure therapy. During 1995-1998, we followed retrospectively travelers who joined rafting trips to an area in Ethiopia where both P. vivax and Plasmodium falciparum are hyperendemic. Of the 106 travelers who received primaquine, 5.7% developed malaria; of the 19 doxycycline recipients, 53% developed malaria; and of the 25 mefloquine recipients, 52% developed P. vivax malaria (>/=3 months after return from the area of endemicity). Primaquine was well tolerated, and only 1 withdrawal from therapy (due to gastrointestinal symptoms) was reported. Primaquine was shown to be a safe and effective prophylactic drug against both P. falciparum malaria and P. vivax malaria in travelers. SN - 1058-4838 UR - https://www.unboundmedicine.com/medline/citation/10585803/Primaquine_as_prophylaxis_for_malaria_for_nonimmune_travelers:_A_comparison_with_mefloquine_and_doxycycline_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/313527 DB - PRIME DP - Unbound Medicine ER -